2007
DOI: 10.1016/j.jacl.2007.10.002
|View full text |Cite
|
Sign up to set email alerts
|

Efficacy of controlled-release niacin in treatment of metabolic syndrome: Correlation to surrogate markers of atherosclerosis, vascular reactivity, and inflammation

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
8
0

Year Published

2009
2009
2024
2024

Publication Types

Select...
7
1
1

Relationship

0
9

Authors

Journals

citations
Cited by 15 publications
(9 citation statements)
references
References 27 publications
(27 reference statements)
1
8
0
Order By: Relevance
“…The median hsCRP reduction of 23% in the present study is consistent with improved vascular reactivity reported for niacin34 and statin 35 treatment. The greater decrease in CRP may reflect its hepatic origin compared to TNFα and IL-6 which reflect inflammation elsewhere, particularly adipose tissue.…”
Section: Discussionsupporting
confidence: 90%
“…The median hsCRP reduction of 23% in the present study is consistent with improved vascular reactivity reported for niacin34 and statin 35 treatment. The greater decrease in CRP may reflect its hepatic origin compared to TNFα and IL-6 which reflect inflammation elsewhere, particularly adipose tissue.…”
Section: Discussionsupporting
confidence: 90%
“…In subjects with the metabolic syndrome, Vaccari et al, Westphal et al, and Thoenes et al demonstrated a significant increases in HDL-C, but Westphal et al failed to show corresponding improvements in flow mediated dilation, while Vaccari et al and Thoenes et al treated subjects with niacin for 52 weeks. 16-18 In subjects with coronary artery disease already on statin therapy, Kuvin et al showed a significant increase in HDL-C and corresponding improvement in FMD, while Andrews et al were unable to show increased FMD despite increasing their subjects’ HDL-C by >25%. 7,19 Warnholtz et al were only able to demonstrate improved FMD in the tertile of subjects who began with HDL-C < 45.…”
Section: Discussionmentioning
confidence: 99%
“…21,22 All of these authors used niacin dosing equivalent to or below our chosen 1500mg, but 3 chose to treat for longer than 12 weeks. 16,18,19,23 Furthermore recently, a meta-analysis was published in JACC, which concluded that while niacin reduces cardiovascular disease events, this reduction was not directly related to patients’ changes in HDL-C. 24,25 …”
Section: Discussionmentioning
confidence: 99%
“…After careful assessment of full-texts, seven articles were found to fulfill the inclusion criteria and were selected for meta-analysis. [15][16][17][18][19][20][21] Reasons for rejecting the other 12 articles were: not measuring FMD, [29][30][31][32][33][34] not having a randomized design, 35 not including an appropriate control group, 36 FMD not being measured in the brachial artery, 37 insufficient data on baseline and/or endpoint FMD values, 22,38 and not being in the English language. 39 A summary of the study selection process is illustrated in Figure 1.…”
Section: Flow Of Included Studiesmentioning
confidence: 99%